Skip to main
RNTX
RNTX logo

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company with promising clinical assets, including LTI-03 and LTI-01, which are positioned to address significant unmet needs in orphan pulmonary and fibrosis indications. Recent data indicating increased sRAGE levels in LTI-03 recipients suggest favorable pharmacodynamic activity, contributing to the stock’s perceived favorable risk-reward profile among investors. The company's potential best-in-class pipeline, targeting areas with limited or inadequate treatment options, enhances the outlook for substantial market opportunities and opportunistic growth over the next 12 months.

Bears say

Rein Therapeutics Inc. has experienced significant share price declines in 2025, with a 50% decrease year-to-date compared to a mere 3.5% decline in the broader XBI index, largely due to the company's decision to pause enrollment in U.S. clinical trials. This pause has introduced uncertainty regarding the progress and viability of its product candidates, particularly LTI-03, which is aimed at treating Idiopathic Pulmonary Fibrosis (IPF). Furthermore, the observed correlation between lower serum receptor for advanced glycation end-products (sRAGE) levels and poor survival rates in IPF patients raises concerns about the clinical efficacy and market potential of Rein's therapeutic developments.

RNTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, RNTX has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.